Bibby Anna C, Tsim Selina, Kanellakis Nikolaos, Ball Hannah, Talbot Denis C, Blyth Kevin G, Maskell Nick A, Psallidas Ioannis
Academic Respiratory Unit, University of Bristol, Bristol ,UK
North Bristol NHS Trust, Bristol, UK.
Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016.
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. There is a global epidemic of malignant pleural mesothelioma underway, and incidence rates are predicted to peak in the next few years.This article summarises the epidemiology and pathogenesis of malignant pleural mesothelioma, before describing some key factors in the patient experience and outlining common symptoms. Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers. Treatment options are summarised, including the importance of palliative care and methods of controlling pleural effusions. The evidence for chemotherapy, radiotherapy and surgery is reviewed, both in the palliative setting and in the context of trimodality treatment. An algorithm for managing malignant pleural effusion in malignant pleural mesothelioma patients is presented. Finally new treatment developments and novel therapeutic approaches are summarised.
恶性胸膜间皮瘤是一种侵袭性的胸膜表面恶性肿瘤,主要由既往接触石棉所致。全球范围内恶性胸膜间皮瘤的发病呈流行趋势,预计发病率将在未来几年达到峰值。本文在描述患者体验中的一些关键因素并概述常见症状之前,先总结了恶性胸膜间皮瘤的流行病学和发病机制。对诊断方法进行了综述,包括成像技术和各种生物标志物的作用。总结了治疗选择,包括姑息治疗的重要性和控制胸腔积液的方法。回顾了化疗、放疗和手术在姑息治疗及三联疗法背景下的证据。提出了一种管理恶性胸膜间皮瘤患者恶性胸腔积液的算法。最后总结了新的治疗进展和新型治疗方法。